
INSTITUTIONAL BIOSAFETY COMMITTEE MEETING DRAFT MINUTES

The University of Texas at San Antonio
Wednesday June 3, 2026
Microsoft Teams Meeting

Minutes Prepared by: Yulissa E. Stevens

MEMBERS PRESENT (7 needed for quorum)

- Dr. Jose Lopez-Ribot, Chair, Voting
- Dr. Janakiram Seshu, Vice-Chair, Voting
- Dr. JiehJuen Yu, Voting
- Dr. Karl Klose, Voting
- Dr. Marcel Perret-Gentil, Voting
- Dr. Jurgen Engelberth, Voting, Plant Specialist
- Dr. Astrid Cardona, Voting
- Mr. Rich Garza, Asst. Director Laboratory Safety & Hazardous Materials Management with vote
- Ms. Yolanda Acosta, *ex officio* Scientific Alternate with vote
- Dr. Ana Vallor, Non-Affiliated, Voting
- Dr. Shannan Hall-Ursone, Non-Affiliated, Voting
- Mr. Anthony Vallejo, *ex officio*, Director of Laboratory Safety, (Scientific Alternate)

GUESTS

- Mrs. Rachel Davis, UTSA Scholarly Resources Librarian
- Ms. Jolyn Demarest, Occupational Health Program non-voting
- Dr. Hamid Badali, Voting, (Scientific Alternate)
- Ms. Yulissa Stevens, Laboratory Safety Specialist non-voting

START: 9:04am

ADJOURN: 9:12am

8 voting members present

I. Review of the Minutes of the Previous IBC Meeting

Review of the March 4th Minutes – Approved

Committee Decision: 8 in favor, 0 opposed, and 0 abstention

II. Review of New or Renewal Applications

In reviewing each protocol discussed below, the committee gave consideration to the following specific concerns, as appropriate:

- a. Adequacy of containment equipment / procedures / facilities to be implemented
- b. Agent characteristics (e.g., virulence, pathogenicity, environmental stability)
- c. Types of manipulations planned
- d. Source(s) of the inserted DNA sequences (e.g., species)
- e. Nature of the inserted DNA sequences (e.g., structural gene, oncogene)
- f. Host(s) and vector(s) to be used
- g. Whether or not an attempt will be made to obtain expression of a foreign gene, and if so, the protein that will be produced.

IBC#0519: Operational Biosafety Protocol for the UTSA Genomics Core

Project Overview

Microbial Agents, Infectious Agents or Toxins
Escherichia coli K12, Saccharomyces cerevisiae
Biosafety Level
BSL-2
Risk Group
RG 1
Section of the NIH Guidelines (if applicable)

Score: 01

Committee Decision: 0 in favor, 0 opposed, and 0 abstention

III. Review of Amendments

In reviewing each protocol discussed below, the committee gave consideration to the following specific concerns, as appropriate:

- a. Adequacy of containment equipment / procedures / facilities to be implemented
- b. Agent characteristics (e.g., virulence, pathogenicity, environmental stability)
- c. Types of manipulations planned
- d. Source(s) of the inserted DNA sequences (e.g., species)
- e. Nature of the inserted DNA sequences (e.g., structural gene, oncogene)
- f. Host(s) and vector(s) to be used
- g. Whether or not an attempt will be made to obtain expression of a foreign gene, and if so, the protein that will be produced.

IBC#

Project Overview

S/N	Amendments	Reviewer comments	Decision
1	MMI 4752 and MMI 5033 – Immunology Teaching Lab	N/A	IBC Chair approved 4.15.26
2	Clanton Lab – Preclinical Pharmacology	N/A	IBC Chair approved 5.1.26

Score

Committee Decision: 0 in favor, 0 opposed, and 0 abstention

IV. Administrative Approvals

S/N	Title	Reviewer comments	Decision
1	Early life lymphatic filariasis infection: environmental, microbial, and immunological dynamics in an endemic region of coastal Ghana – Melissa Manus, Anthropology	N/A	IBC Chair Approved 4.9.2026

V. Expired / Closed Protocols

None at this time

VI. New Business

[Redacted content]

VII. Adjourn

The meeting was adjourned at 9:12a.m. Next meeting will take place on Wednesday, July 1st, 2026 at 9:00am via Teams.

X 

Jose Lopez-Ribot
IBC Chair